Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219866 · ClinicalTrials.gov registry record · Phase 4
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03219866 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants.
The verdict
NCT03219866, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease (COPD) exacerbation patients. We hypothesize that patients treated in hospital and discharged on respiratory medications administered by nebulizers will exhibit better quality of life (QoL), symptom control, and lower COPD and all cause hospital readmission rates compared with patients treated with respiratory medications delivered by DPI. We aim to demonstrate that: 1. Patients treated and discharged on nebulized bronchodilators will have fewer readmissions to hospital at 30 and 90 days compared to the group utilizing DPI 2. The nebulizer group will demonstrate a longer duration of time until hospital readmission for COPD and all cause readmission compared to the group utilizing DPI 3. The nebulizer group will demonstrate better QoL (measured by the SGRQ - Saint George Respiratory Questionnaire) and symptom control (as measured by the CAT \& mMRC) compared to the group utilizing DPI.
Interventions
- DEVICE Dry Powder Inhaler
- DRUG Pulmicort
- DEVICE Nebulizers
- DRUG Brovana
- DRUG Atrovent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219866
The ClinicalTrials.gov registry entry for NCT03219866 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dry Powder Inhaler is the first listed.
NCT03219866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03219866 about?
NCT03219866 is a clinical study titled "Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)". This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease (COPD) exacerbation patients. We hypothesize that patients treated in hospital and discharged on respiratory medicatio...
What is the current status of trial NCT03219866?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-10-03. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT03219866?
The interventions under investigation include: Dry Powder Inhaler (DEVICE), Pulmicort (DRUG), Nebulizers (DEVICE), Brovana (DRUG), Atrovent (DRUG).
Who is sponsoring clinical trial NCT03219866?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.